{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:27:55Z","timestamp":1762234075039,"version":"build-2065373602"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer contributes significantly to the morbidity and mortality rates for women worldwide. As observed with other types of cancer, health disparities disproportionately affect ovarian cancer incidence rates and outcomes, especially in African American and older women. However, the trends in ovarian cancer mortality rates up until 2023 with regard to various demographic identifiers have not been fully elucidated, which this study aims to rectify.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mortality trends due to malignant neoplasms of the ovary in individuals 25 and older in the US from 1999 to 2023 were analyzed using the Centers for Disease Control Wide Ranging Online Data for Epidemiological Research (CDC WONDER) database. Trends in age-adjusted mortality rate (AAMR) were analyzed on the basis of race, 10-year age-group, region and urban\/rural designation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 1999 and 2023, the AAMR related to malignant neoplasms of the ovary fell from 14.62 in 1999 to 9.52 in 2023. All races analyzed saw a decrease in overall mortality related to malignant neoplasms of the ovary, with the largest decrease being observed in White patients (AAPC: -1.78). Regionally, the Northeast (AAPC: -1.95), Midwest (AAPC: -1.99), South (AAPC: -1.72), and West (AAPC: -1.73) regions of the United States (US) all saw reduced ovarian neoplasm mortality rates. Similarly, rates also decreased in urban (AAPC: -1.83) and rural (AAPC: -1.75) localities, as well as in each ten-year age category analyzed, with the largest decrease seen in the 55\u201364 years old category (AAPC: -2.15). States such as Delaware, South Carolina, and Idaho experienced some of the largest decreases in AAMR, whereas the District of Columbia saw an increase in AAMR during this period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over the last twenty-years, mortality rates for malignant neoplasms of the ovary have declined, with the largest decreases being seen in White patients, those residing in the Midwest, urban locality, and women between 55\u201364 years olds. While mortality rates have declined, health disparities still continue to negatively affect ovarian cancer outcomes, and more research is needed to improve accessibility, availability, and affordability of care for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1691932","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:23:02Z","timestamp":1762233782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overarching view of trends and disparities in malignant neoplasm of the ovary between 1999-2023: a comprehensive CDC WONDER database study"],"prefix":"10.3389","volume":"15","author":[{"given":"Jaikin","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Murillo Armenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abubakar","family":"Tauseef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0000000000000923","article-title":"A review of racial disparities in ovarian cancer and clinical trials","volume":"36","author":"Ali","year":"2023","journal-title":"Curr Opin Obstetrics Gynecology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13048-017-0352-1","article-title":"Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among blacks and whites","volume":"10","author":"Sakhuja","year":"2017","journal-title":"J Ovarian Res"},{"key":"B3","doi-asserted-by":"crossref","unstructured":"Chornokur\n              G\n            \n            \n              Amankwah\n              EK\n            \n            \n              Schildkraut\n              JM\n            \n            \n              Phelan\n              CM\n            \n          \n          Global ovarian cancer health disparities.\n          \n          2013","DOI":"10.1016\/j.ygyno.2012.12.016"},{"key":"B4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/aog.0000000000005210","article-title":"Health disparities in ovarian cancer","volume":"142","author":"Mei","year":"2023","journal-title":"Obstetrics Gynecology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9161","article-title":"Trends in cardiometabolic mortality in the United States 1999-2017","volume":"322","author":"Shah","year":"2019","journal-title":"JAMA"},{"key":"B6","unstructured":"Joinpoint regression software\n          \n          2025"},{"key":"B7","volume-title":"Number of permuted data setsJoinpoint help system","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributab le risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"2025","journal-title":"J\u00a0Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182a92011","article-title":"Racial disparities in the treatment of advanced epithelial ovarian cancer","volume":"122","author":"Howell","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-17-0290","article-title":"Recent trends in ovarian cancer incidence and relative survival in the United States by race\/ethnicity and histologic subtypes","volume":"26","author":"Park","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.08.035","article-title":"Racial disparities and patterns of ovarian cancer surgical care in California","volume":"132","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol"},{"key":"B12","volume-title":"Racial Misclassification and Disparities in Mortality among AI\/AN and Other Races","year":"2014"},{"key":"B13","article-title":"Racial misclassification and disparities in mortality among American Indians\/Alaska Natives and other races","volume-title":"Race and ethnicity data improvement toolkit.","author":"Dankovchik","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2016.11.006","article-title":"Cancer care access and outcomes for American Indian populations in the United States: Challenges and models for progress","volume":"27","author":"Guadagnolo","year":"2017","journal-title":"Semin Radiat. Oncol"},{"key":"B15","volume-title":"Walking Forward Program strives to mend cancer disparities in American Indians","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091397","article-title":"Influence of age on treatment and prognosis in ovarian cancer patients","volume":"17","author":"Mancebo","year":"2025","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2025.103030","article-title":"Initial and persistent changes in cancer screening in a US midwestern community health center network following the onset of COVID-19","volume":"53","author":"An","year":"2025","journal-title":"Prev Med Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0003406","DOI":"10.1371\/journal.pgph.0003406","article-title":"Changes in reasons for visits to primary care after the start of the COVID-19 pandemic: An international comparative study by the International Consortium of Primary Care Big Data Researchers (INTRePID)","volume":"4","author":"Tu","year":"2024","journal-title":"PloS Glob Public Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1691932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:23:05Z","timestamp":1762233785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1691932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1691932"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1691932","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"1691932"}}